Lenalidomide proved effective in multisystem Langerhans cell histiocytosis
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Acta Oncologica |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.3109/0284186X.2011.631581 |
| Field | Oncology and hematology |
| Keywords | Langerhans cell histiocytosis; lenalidomide; PET/CT |
| Description | Langerhans cell histiocytosis (LCH) is a rare idiopathic disease with diverse clinical manifestations ranging from a single osteolytic lesion to generalized disease. Various treatment regimens have been proposed for the multisystem type, however, with inconsistent outcomes. Herein we are the first to report on a therapy effect of a lenalidomide-based regimen in a patient with repeatedly relapsed aggressive form of multisystem LCH. |
| Related projects: |
|